| KIN Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the KIN shares outstanding history going back to 12/12/2013:
Also see: KIN Market Cap History KIN YTD Return |
KIN Shares Outstanding History — Kindred Biosciences Share Count Over Time
As of 7/31/2021 Kindred Biosciences has 45.46 million KIN shares outstanding. Investors often track the KIN shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows KIN share count trends over time, with 35 historical shares outstanding datapoints presented, dating back to 12/12/2013.
| KIN Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
KIN Historical Shares Outstanding: +17.47% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| KIN Stock Price Chart |
| About Kindred Biosciences Inc |
| Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Co.'s portfolio includes: Mirataz®, which is its transdermal drug for the management of weight loss in cats; and Zimeta™, which is for the control of pyrexia in horses. Co.'s product candidates include: KIND-016, a fully caninized monoclonal antibody targeting interleukin-31 for the treatment of atopic dermatitis in dogs; KIND-032, a fully caninized monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; and KIND-025, a canine fusion protein targeting IL-4 and IL-13, for the treatment of atopic dermatitis in dogs. We show 35 historical shares outstanding datapoints in our coverage of KIN's shares outstanding history. Understanding the changing numbers of KIN shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like KIN versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching KIN by allowing them to research KIN shares outstanding history as well as any other stock in our coverage universe. |
| KIN Current Stock Quote |
Quotes delayed 20 minutes  Free KIN Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| KIN Share Performance |
| Shares Outstanding Peers |
| Kindred Biosciences (KIN) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
KLDO Shares Outstanding History KLRS Shares Outstanding History KMPH Shares Outstanding History KND Shares Outstanding History KNTE Shares Outstanding History KOD Shares Outstanding History KOOL Shares Outstanding History KPRX Shares Outstanding History KPTI Shares Outstanding History KRBP Shares Outstanding History More Healthcare companies » |
KIN Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
